Glutathione Peroxidase Codon 198 Polymorphism Variant Increases Lung Cancer Risk

Duminda Ratnasingham, Joseph A. Tangrea, Mark R. Andersen, Michael J. Barrett, Jarmo Virtamo, Philip R. Taylor, and Demetrius Albanes

Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892-7058 [D. R., J. A. T., P. R. T., D. A.]; New Chemical Entities, Inc., Bothell, Washington 98011 [M. R. A.]; Information Management Services, Inc., Silver Spring, Maryland 20904 [M. J. B.]; and National Public Health Institute, SF–00300 Helsinki, Finland [J. V.]

ABSTRACT

Human cellular glutathione peroxidase 1 (hGPX1) is a selenium-dependent enzyme that participates in the detoxification of hydrogen peroxide and a wide range of organic peroxides. We conducted a case-control study nested within the α-Tocopherol, β-Carotene Cancer Prevention Study cohort to evaluate the association between the proline to leucine polymorphism at codon 198 of hGPX1 and lung cancer risk. Cases (n = 315) were matched to controls on age (±5 years), intervention group, and study clinic using incidence density sampling in a 1:1 ratio. The prevalence of the hGPX1 Pro198Leu variant allele was 58% for controls and 71% for cases (P < 0.001). Using conditional logistic regression, we found a significant association between hGPX1 genotype and lung cancer risk. The odds ratio for heterozygotes was 1.8 (95% confidence interval, 1.2–2.8) and 2.3 (95% confidence interval, 1.3–3.8) for homozygous variants compared to wild-type individuals. Due to its high prevalence, the hGPX1 variant may contribute significantly to lung cancer risk among Caucasians but not among ethnic Chinese who do not exhibit this polymorphism.

INTRODUCTION

Although environmental and industrial exposures such as radon can increase lung cancer risk, it is well established that tobacco smoke is principally responsible for the incidence of this malignancy. However, not all persons exposed to high concentrations of airborne carcinogens develop lung cancer. Differences in lung cancer risk among individuals with similar carcinogen exposures may be due to genetic predisposition and dietary factors that have been shown to modulate or neutralize carcinogen-derived oxidative radicals.

The risk of developing cancer is determined by both the number and nature of cumulative carcinogenic exposures and by individual genetic variation (1). For example, genetic polymorphisms in detoxification enzymes can substantially alter the magnitude of exposure to carcinogenic substances. hGPX13 is a selenium-dependent enzyme that participates in the detoxification of hydrogen peroxide and a wide range of organic peroxides with reduced glutathione (2). From a sequence analysis of lung tumor specimens, Moscow et al. (3) reported a nucleotide substitution at codon 198 of hGPX1, resulting in the substitution of leucine for proline. They also reported that other polymorphisms cosegregate with the proline to leucine substitution, including six alanines in the polyalanine sequence (instead of five or seven alanines with the wild-type proline), a T for C substitution at position 198 of hGPX1, and a wide range of organic peroxides. We conducted a case-control study nested within the α-Tocopherol, β-Carotene Cancer Prevention Study cohort to evaluate the association between the proline to leucine polymorphism at codon 198 of hGPX1 and lung cancer risk. Cases (n = 315) were matched to controls on age (±5 years), intervention group, and study clinic using incidence density sampling in a 1:1 ratio. The prevalence of the hGPX1 Pro198Leu variant allele was 58% for controls and 71% for cases (P < 0.001). Using conditional logistic regression, we found a significant association between hGPX1 genotype and lung cancer risk. The odds ratio for heterozygotes was 1.8 (95% confidence interval, 1.2–2.8) and 2.3 (95% confidence interval, 1.3–3.8) for homozygous variants compared to wild-type individuals. Due to its high prevalence, the hGPX1 variant may contribute significantly to lung cancer risk among Caucasians but not among ethnic Chinese who do not exhibit this polymorphism.

PATIENTS AND METHODS

Study Cohort. The cases and controls for this study were selected from the cohort of the α-Tocopherol, β-Carotene Cancer Prevention Study, a randomized, placebo-controlled prevention trial designed to determine whether α-tocopherol (50 mg/day), β-carotene (20 mg/day), or both would reduce the incidence of lung, prostate and other cancers. The overall design, rationale, and objectives of this study have been published, as have the main trial findings (4–6). The trial was conducted between 1985 and 1993 in southwestern Finland as a joint project between the National Public Health Institute of Finland and the National Cancer Institute of the United States. Potential participants, all men aged 50–69 years residing in southwestern Finland (n = 290,486) were identified from the computer list of the national population register of Finland. Participants (29,133) had to be current smokers of five or more cigarettes per day, eligible and willing to participate, and give informed consent. Information on variables that possibly could confound the association between the polymorphism of hGPX1 and lung cancer risk were available from α-Tocopherol, β-Carotene Cancer Prevention Study baseline questionnaires. Baseline measurements of serum α-tocopherol and β-carotene levels were also available.

Selection of Cases and Controls. The cases consist of 315 men diagnosed with primary lung cancer (ICD-9, 162) during the years 1985–1994 among those who gave a whole blood sample in 1992 and 1993. Seventy-eight percent of the cases donated blood before cancer diagnosis. Using incidence density sampling, the controls were selected from cohort participants who were alive and free of cancer at the time the matched case was diagnosed. Controls were selected from those who donated blood matched to cases on age (±5 years), intervention group, and study clinic in a 1:1 ratio.

Genotype Analyses. PCR primers and dual-labeled allele discrimination probes were designed using PrimerExpress version 1.0 (PE Biosystems). Probes were selected that have a predicted Tm near 68°C, with the polymorphic base near the center. Flanking PCR primers were selected based on the calculated penalty score, Tm length, and amplicon size. Primers and probes were synthesized and purified by PE Biosystems. Oligonucleotide sequences for primers and probes to detect the C to T polymorphism in codon 198 of hGPX1 were: PCR forward, TGGTCCCCTACGGAGTACA; PCR reverse, CCCCCGGACACGGCA; C allele probe, 5′-CTGTCCTCGAAGGGCCTAATTGGTGAATTCC-3′; T allele probe, 5′-CTGTCCTCAGGGCGTACAGTCGTTTATGATTCC-3′. Reactions (10 μl) contained 20 ng of genomic DNA isolated from whole blood, 1× TaqMan Master Mix, dual-labeled probes (100 nM each), and PCR primers (900 nM each). Reactions were performed in 96-well MicroAmp Optical reaction plates and caps (PE Biosystems), Plates were incubated in PE Biosystems 9600 thermal cyclers at 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 62°C for 1 min. Fluorescence was measured using the ABI Prism 7700 Sequence Detector and analyzed with Sequence Detection System version 1.6.3. Amplified DNA from several individuals exhibiting each genotype was electrophoresed on an agarose gel to confirm amplicon size and sequenced to confirm each genotype. When possible, each plate contained two control DNA samples for each homozygous genotype and

Received 3/2/00; accepted 9/13/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by USPHS National Cancer Institute contract NO1-CN45165 from the National Cancer Institute, NIH, Department of Health and Human Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the United States Government.

To whom requests for reprints should be addressed, at Division of Clinical Sciences, Cancer Prevention Studies Branch, 6006 Executive Boulevard, MSC 7058, Bethesda, MD 20892-7058. E-mail: DR132K@NIH.gov.

The abbreviation used is: hGPX1, human glutathione peroxidase 1.
RESULTS

Table 1 shows a case-control comparison of selected baseline subject characteristics. As expected, cigarette smoking and age-started smoking were significantly different in the cases compared with controls. Levels of serum antioxidants, α-tocopherol, and β-carotene were not different in lung cancer cases compared with controls.

Table 2 shows the association between the hGPX1 genotype and lung cancer risk. The distribution of hGPX1 alleles was different comparing the cases with controls ($\chi^2$ $P$ for distributions <0.001). In addition, we observed an association between the hGPX1 genotype and lung cancer risk. Individuals with the heterozygous genotype were at 80% greater risk for lung cancer compared to those with the homozygous wild-type (pro/pro) genotype. Individuals with the homozygous variant genotype (leu/leu) were at 130% greater risk for lung cancer compared with homozygous wild-type individuals. Adjustment for baseline covariates such as years smoked or cigarettes smoked per day did not materially alter the risk estimates. However, the risk estimates shown in Table 2 were adjusted for years smoked and cigarettes smoked per day because they were significantly associated with lung cancer risk.

We also evaluated the association between the hGPX1 genotype and histological subtypes of lung cancer. The relative risk estimates for squamous cell ($n = 140$), odds ratio homozygous wild type, heterozygous variant, and homozygous variant; 1.0, 2.4, and 3.2, respectively) and adenocarcinoma ($n = 56$), odds ratio homozygous wild type, heterozygous variant, and homozygous variant; 1.0, 3.9, and 3.3, respectively) of the lung were statistically significant for both the heterozygous and homozygous variant genotypes compared to those with the homozygous wild-type genotype. By contrast, risk of small cell lung carcinoma ($n = 49$) was not associated with hGPX1, possibly due to the relatively small number of cases for this subtype.

Evaluation of age, cigarette smoking, serum α-tocopherol and/or β-carotene at baseline, and trial intervention of α-tocopherol and/or β-carotene as potential modifiers of the association between hGPX1 and lung cancer risk showed no statistically significant interactions (data not shown).

DISCUSSION

A large proportion of lung cancers have a deletion of the short arm of chromosome 3, in the region of 3p21 (7, 8). hGPX1 is a selenium-dependent detoxifying enzyme that has been mapped to chromosome 3p21 by in situ hybridization of lymphocyte metaphase spreads (3). Glutathione peroxidases protect cells against oxidative damage by reducing hydrogen peroxide and a wide range of organic peroxides with reduced glutathione (2). The cytosolic form of GPX1 belongs to a family of selenium-dependent peroxidases that include another cystolic form, hGPX2 (9), the plasma-based hGPX3 (10), and the phospholipid hydroperoxidase hGPX4 (11).

Many studies have shown that selenium increases hGPX1 activity and expression (12–14). It is generally assumed that selenium increases the antioxidant capacity of a cell, consequently reducing intracellular oxidative stress. The association between prospectively collected serum selenium and lung cancer has been reported in over a dozen studies (15–19). Most of these studies found that selenium concentrations were slightly lower in the lung cancer cases than in controls.

In the current study, we confirm the presence of a germ-line polymorphism in the coding region of hGPX1 with notable prevalence of allele variants among middle-aged Finnish smokers. We also show that individuals with one or two variant alleles were at increased risk of lung cancer compared with homozygous wild-type individuals. One possible explanation for the increased lung cancer risk observed among individuals with just one variant allele is that, because different hGPX1 alleles encode structurally different hGPX1 subunits, heterozygote individuals may have a less efficient final glutathione peroxidase complex. In addition, serum antioxidant levels or supplements of α-tocopherol (50 mg daily) or β-carotene (20 mg daily) did not seem to modify lung cancer risk associated with the variant hGPX1 genotypes. This may be due to lack of chemical reactivity of α-tocopherol and/or β-carotene with hydrogen peroxide or organic peroxides. Smoking also did not modify the risk of lung cancer due to hGPX1 variants.

The association we report here is complicated by the other polymorphisms that cosegregate with the codon 198 polymorphism. These polymorphisms include six alanines in the hGPX1 polyalanine sequence (instead of five or seven alanines with the wild-type proline), a T for C substitution at +2, and a G for A substitution at −592 with the proline to leucine substitution. Although the exact structural or functional consequences of these hGPX1 coding region polymorphisms are not known, the substitution of the α-imino acid proline (cyclic amino acid) by leucine is probably the polymorphism that causes the most profound secondary and tertiary conformational change of hGPX1, because proline is the only amino acid without a
free unsubstituted amino group on the α carbon atom and is known to cause a unique kink in the secondary structure of peptides.

One of the strengths of this study is its prospective design. The collection of covariates (e.g., smoking) before case diagnoses minimized the potential for recall bias. The availability of detailed exposure data also allowed us to explore several relevant gene-environment interactions. The availability of data on prospective serum antioxidant levels and supplements of α-tocopherol or β-carotene given during the intervention trial added another dimension to our study because of the antioxidant functions of hGPX1. The generalizability of these results, however, may be somewhat restricted because the study was conducted among Finnish male smokers. Other case-control studies examining the association of hGPX1 polymorphisms and lung cancer risk are clearly needed. In future studies, our group will attempt to examine the association between the hGPX1 polymorphism and lung cancer risk in other Caucasian populations. Our analysis of ethnic Chinese members of the Yunnan tin corporation cohort (20) revealed that they do not exhibit the codon 198 polymorphism and lung cancer risk in other Caucasian populations. Other case-control studies examining the association of hGPX1 polymorphisms and lung cancer risk are clearly needed. In future studies, our group will attempt to examine the association between the hGPX1 polymorphism and lung cancer risk in other Caucasian populations. Our analysis of ethnic Chinese members of the Yunnan tin corporation cohort (20) revealed that they do not exhibit the codon 198 hGPX1 polymorphism (all 92 noncase samples analyzed were wild type).

In summary, we show that the codon 198 hGPX1 polymorphism is associated with increased risk of lung cancer among male smokers. We also found that neither smoking nor supplementation with either α-tocopherol and/or β-carotene altered the association between the hGPX1 allele and increased risk of lung cancer. Because of its high prevalence, the codon 198 allele of hGPX1 may have substantial public health impact by influencing lung cancer risk among Caucasians but not among ethnic Chinese.

REFERENCES

Glutathione Peroxidase Codon 198 Polymorphism Variant Increases Lung Cancer Risk

Duminda Ratnasinghe, Joseph A. Tangrea, Mark R. Andersen, et al.

*Cancer Res* 2000;60:6381-6383.

Updated version

Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/22/6381

Cited articles

This article cites 19 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/60/22/6381.full.html#ref-list-1

Citing articles

This article has been cited by 35 HighWire-hosted articles. Access the articles at:
/content/60/22/6381.full.html#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.